SR ONE CAPITAL MANAGEMENT, LP Q2 2025 Filing
Filed August 14, 2025
Portfolio Value
$461.4B
Holdings
13
Report Date
Q2 2025
Filing Type
13F-HR
All Holdings (13 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | ACLXArcellx, Inc. | 2,346,630 | $154.5B | 33.49% | |
| 2 | SPRYARS Pharmaceuticals, Inc. | 4,012,903 | $70.0B | 15.18% | |
| 3 | CRSPCRISPR Therapeutics AG | 1,048,951 | $51.0B | 11.06% | |
| 4 | ZBIOZenas BioPharma, Inc | 4,911,539 | $47.6B | 10.32% | |
| 5 | ORICORIC Pharmaceuticals, Inc. | 4,514,929 | $45.8B | 9.93% | |
| 6 | MLYSMineralys Therapeutics Inc. | 3,127,933 | $42.3B | 9.17% | |
| 7 | DSGNDesign Therapeutics, Inc. | 6,526,476 | $22.0B | 4.77% | |
| 8 | OCSOculis Holding AG | 322,500 | $6.3B | 1.36% | |
| 9 | ALMSAlumis Inc. | 1,959,896 | $5.9B | 1.27% | |
| 10 | NKTXNkarta, Inc. | 3,333,333 | $5.5B | 1.20% | |
| 11 | ORKAOruka Therapeutics, Inc | 430,330 | $4.8B | 1.05% | |
| 12 | KALAKALA Bio, Inc. | 598,940 | $2.9B | 0.62% | |
| 13 | ENGNenGene Holdings Inc. | 747,750 | $2.7B | 0.59% |